Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
We should focus on the strong commercial experience of Shaun Chilton the new non exec director. Greatly strengthens the board. Also good to see Eliot Forster adding his name and reputation to Avacta’s progress
Hi
Sorry for slow reply don’t watch the board that much. I emailed Simon as he mentioned that date was on the website but I couldn’t find it. Unusually he didn’t reply so rather than bothering him again I just phoned the SRT office. Lady on end of phone checked her calendar and confirmed date. Suggest you ring again just to make 100% sure but she did seem certain.
The shareholder event at the AGM can only be taken as a statement of confidence. I think this is Alastair’s way of saying don’t just take my word for it come and talk to our top scientists and hear the same story from them. A lot of senior scientists will be putting their reputations on the line. Just patience required. Hopefully shareholders will take up all the AGM places offered.
One day I’m going to register on Advfn. To answer the AGM question it’s on Wednesday 20/9. Unfortunately I’m away and will miss AGM for the first time in about 7 years. Shame it should be a celebration, one that’s been ‘imminent’ for quite a while
Sorry saw the topic heading
‘We would never try to dilute shareholders’
Bell saying that defies belief and years of dilution and he accuses others of lying. If it wasn’t so depressing it would be funny.
I urge all shareholders & potential investors to watch this mornings webinar and unlike most Aim companies I believe it can be taken at face value. Their AGMs are second to none and give clear insight into the direction of the company. So attend if at all possible. There was I think 5 years ago a ‘jam today’ AGM. It’s only taken another 5 years…….but who’s counting.
As Eric Morecambe once said they are all the right notes just not necessarily in the right order. Over the years Simon has projected pretty accurately what SRT could achieve in a developing global market he just hasn’t been remotely close with the timescale. I believe SRT are now on the verge of a seriously successful business. Unfortunately like so many UK companies they will no doubt be bought out before they realise their full value.
First time in 4 years I’ve bought more shares as I already have too many but no news in the trial is simply good news. To me the end of the phase is a win win scenario, if no further escalation we can move on with 1b, and if it is Prof Twelves was correct when he said nowhere near finding MTD. I believe AGM rns is imminent so get there if you possibly can. It is planned to be more of an investor event with most of the senior scientists there. I am really looking forward to hearing firsthand from Neil, Fiona et al about the preCISION feedback from the American conferences. Upwards and onwards……….Hopefully!
Dr Tap taking the time and effort to attend little Avacta’s Science Day speaks volumes. First patient dosed so quickly confirms belief in AVA6000 potential. If proven and of course it still is a big if who can forget his ‘ Overnight it will become Standard of Care for STS’ Very Exciting times. Now if only Prodox acted like ‘Chalk and Cheese’ in the body……
Hi
This is my 6 monthly post. Please anyone thinking of investing in this company do some serious research. I lost all my money invested here years ago as have many others. Nothing changes. How Bell is still allowed to run this as his own income source I do not know. A sad indictment of the Aim market. Investors BEWARE AVOID.
For those who asked I believe the reason for the presentation titles from Doctors Komanduri & Tap was to make the subject matter more ‘interesting’ I found the number of questions from the floor pathetic. A sad comment on our Institutional Investors. Actually it was beyond pathetic and maybe completely explains their lack of knowledge and investment. What is happening in the US again I have absolutely no idea. I heard 6 months ago MSK and Fred Hutch were going to be involved but that could have been ongoing. Orphan drug status no idea. STS work to date no idea, why have no patients been enrolled in the US to date no idea. Generally at the moment ????? ????? ?????
Timelines no idea, route to commercialism no idea,……but haven’t sold a single share yet and believe Avacta has a ‘tiger by the tail’ and just needs to work out what to do with it before someone else decides for them. We await the Prelims
I am in no doubt that Avacta’s scientists believe in preCISION. I was lucky enough to visit White City last May. Neal almost in passing said ‘We know what we’ve got’ Since then the data has remained ‘remarkably consistent’ On the Science Day I asked Fiona what I thought was a perfectly reasonable question ‘Is this perceived delay in DE5 just normal regulatory challenges’ she replied ‘Nice try’ So I have no idea whether DE5 is underway but I am certain after discussion with Prof Twelves who could not contain his enthusiasm for the trial to date that it’s all systems go. He did mention it might be possible to escalate the dose within a cohort but he was talking hypothetically. So to repeat I have no idea what is going on
PAH
That was my hope but I wasn’t sure and didn’t want to post something that could be a ramp. The data / information confirmed at the Science Day means one thing for sure…..AVACTA DOES NOT NEED RAMPING the data speaks for itself
PAH004……Prof Chris Twelves
I spoke to Chris for 5 minutes odd in a coffee break. I have never met him before but I can only agree he was VERY enthusiastic. He could currently only draw the conclusion, as he does say in the Q&A for Fiona, that preCISION does do what it ‘says on the tin’ He double downed on difficulty on finding a MTD and did then talk about different ways that ‘hypothetically’ this could be approached by adjusting the clinical trial. I asked the direct DE5 (delay?) question to Alastair Fiona & Chris and got unsurprisingly blanked.
Yep let’s see the slides from memory lowest was a nine the rest were much higher. Definitely two over a hundred maybe 117 and 127. Amazing results we couldn’t get over the 100 scores maybe average was 100 but as excitement fades maybe average nearer 80. 80 is almost unbelievable!!! In fact I think most of the preCISION data to date is unbelievable which is the problem. Analyse over the weekend and draw your own conclusions